These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 17502861)

  • 1. Tumor necrosis factor blockade: mechanism of action.
    Gottlieb AB
    J Investig Dermatol Symp Proc; 2007 May; 12(1):1-4. PubMed ID: 17502861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor.
    Kaymakcalan Z; Sakorafas P; Bose S; Scesney S; Xiong L; Hanzatian DK; Salfeld J; Sasso EH
    Clin Immunol; 2009 May; 131(2):308-16. PubMed ID: 19188093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding characteristics of tumor necrosis factor receptor-Fc fusion proteins vs anti-tumor necrosis factor mAbs.
    Kohno T; Tam LT; Stevens SR; Louie JS
    J Investig Dermatol Symp Proc; 2007 May; 12(1):5-8. PubMed ID: 17502862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reactivation of latent tuberculosis by TNF blockade: the role of interferon gamma.
    Wallis RS
    J Investig Dermatol Symp Proc; 2007 May; 12(1):16-21. PubMed ID: 17502864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of etanercept are distinct from infliximab in modulating proinflammatory genes in activated human leukocytes.
    Haider AS; Cardinale IR; Whynot JA; Krueger JG
    J Investig Dermatol Symp Proc; 2007 May; 12(1):9-15. PubMed ID: 17502863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab.
    Mitoma H; Horiuchi T; Tsukamoto H; Tamimoto Y; Kimoto Y; Uchino A; To K; Harashima S; Hatta N; Harada M
    Arthritis Rheum; 2008 May; 58(5):1248-57. PubMed ID: 18438840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weight gain and tumour necrosis factor-alpha inhibitors in patients with psoriasis.
    Tan E; Baker C; Foley P
    Australas J Dermatol; 2013 Nov; 54(4):259-63. PubMed ID: 24164178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review.
    Tracey D; Klareskog L; Sasso EH; Salfeld JG; Tak PP
    Pharmacol Ther; 2008 Feb; 117(2):244-79. PubMed ID: 18155297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New strategies to address the pharmacodynamics and pharmacokinetics of tumor necrosis factor (TNF) inhibitors: A systematic analysis.
    Meroni PL; Valentini G; Ayala F; Cattaneo A; Valesini G
    Autoimmun Rev; 2015 Sep; 14(9):812-29. PubMed ID: 25985765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fungal infections complicating tumor necrosis factor alpha blockade therapy.
    Tsiodras S; Samonis G; Boumpas DT; Kontoyiannis DP
    Mayo Clin Proc; 2008 Feb; 83(2):181-94. PubMed ID: 18241628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets in Patients with Psoriasis.
    Gibellini L; De Biasi S; Bianchini E; Bartolomeo R; Fabiano A; Manfredini M; Ferrari F; Albertini G; Trenti T; Nasi M; Pinti M; Iannone A; Salvarani C; Cossarizza A; Pellacani G
    PLoS One; 2016; 11(12):e0167757. PubMed ID: 27936119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
    Gniadecki R; Kragballe K; Dam TN; Skov L
    Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis.
    Saraceno R; Schipani C; Mazzotta A; Esposito M; Di Renzo L; De Lorenzo A; Chimenti S
    Pharmacol Res; 2008 Apr; 57(4):290-5. PubMed ID: 18400510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor necrosis factor blockers influence macrophage responses to Mycobacterium tuberculosis.
    Harris J; Hope JC; Keane J
    J Infect Dis; 2008 Dec; 198(12):1842-50. PubMed ID: 18954258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
    JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Differences in pharmacology of tumor necrosis factor (TNF) antagonists].
    Fiocco U; Bombardieri S
    Reumatismo; 2005; 57(4 Suppl):8-16. PubMed ID: 16385350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug insight: different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior?
    Rigby WF
    Nat Clin Pract Rheumatol; 2007 Apr; 3(4):227-33. PubMed ID: 17396108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Observational case series on a group of psoriasis patients who failed to respond to any TNF blockers.
    Viguier M; Livideanu C; Beylot-Barry M; Richard MA; Paul C; Bachelez H; Aubin F;
    J Dermatolog Treat; 2014 Feb; 25(1):75-7. PubMed ID: 23724854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study.
    Esposito M; Gisondi P; Cassano N; Ferrucci G; Del Giglio M; Loconsole F; Giunta A; Vena GA; Chimenti S; Girolomoni G
    Br J Dermatol; 2013 Sep; 169(3):666-72. PubMed ID: 23647206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.
    Bonafede M; Fox KM; Watson C; Princic N; Gandra SR
    Adv Ther; 2012 Aug; 29(8):664-74. PubMed ID: 22886712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.